Aesculap's 1995 sales rise 3.8%
This article was originally published in Clinica
Despite difficult business conditions, Aesculap achieved a 3.8% rise in sales to DM 544.8 million ($390 million) during fiscal 1995 (ended September 30th). In the German company's home market, turnover increased 7.2% to DM 186.5 million, while Asia showed very healthy growth, up 11.2% to DM 81.5 million. Exchange rate effects caused US sales to fall 5.2% in Deutschmark terms, although expressed in dollars they grew 7.4%.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.